Optimizing Malaria Treatment for HIV-Malaria Co-infected Individuals
Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
Optimal is a Randomized clinical trial to optimize treatment of malaria in HIV -malaria co
infected patients. It has been demonstrated that, when the antimalarial drug Artemether
Lumefantrine is co administered with Efavirenz based ART in HIV-malaria co-infected
individuals, sub therapeutic levels of the drug are achieved hence resulting in poor malaria
treatment outcomes.
The study then hypothesizes that, : HIV-malaria co-infected individuals receiving
efavirenz-based ART plus a double-dose or 5-day course of artemether-lumefantrine will
achieve higher and adequate artemether-lumefantrine serum concentrations with adequate 42-day
treatment outcomes compared to individuals with HIV-malaria co-infection receiving
efavirenz-based ART plus a standard-dose of artemether-lumefantrine.
Phase:
Phase 4
Details
Lead Sponsor:
Makerere University
Treatments:
Artemether Artemether, Lumefantrine Drug Combination Dolutegravir Efavirenz Lumefantrine